Terry Fry

Company: Sana Biotechnology, Inc.Institute

Job title: Senior Vice President, Head of T Cell Therapeutics

Seminars:

Hypoimmune & In Vivo Delivery Platforms to Enable Off-The-Shelf CAR-T Cell Therapies 9:30 am

The complexities in manufacturing autologous products limits access to highly effective CAR-T cell therapy Allogeneic T-cells manufactured using Sana’s hypoimmune technology evade both innate and adaptive immunity Sana’s gene delivery platform efficiently generates a functional CAR-T cell in vivoRead more

day: Day One